Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/OYaAKfxxjdg/228314.php
Monday, 13 June 2011
Adaptimmune Announces Opening Of Phase I/II Clinical Trial For Metastatic Melanoma At Washington University, St. Louis
Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri. Adaptimmune is focused on the use of T-cell therapy to treat cancer, with the body's own machinery - the T lymphocyte -- a cell that is being used to target and destroy cancerous cells...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment